IP Library Granted Patent US 9,931,336
Granted Patent B2
US 9,931,336 · App. 15/236,625 · Granted Apr 3, 2018

Combination therapy

Inventors: Casey Kopczynski (Chapel Hill, NC); Cheng-Wen Lin (Raleigh, NC); Jill Marie Sturdivant (Chapel Hill, NC); Mitchell A. deLong (Chapel Hill, NC)
Assignee: Aerie Pharmaceuticals, Inc.
A61K31/472A61K9/0048A61K9/08A61K31/4725A61K31/557A61K31/559A61K31/5575A61K47/481C07D217/22C07D409/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,931,336
App. No.
15/236,625
Granted
Apr 3, 2018
Kind
B2
Abstract

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Claims (21)

1. A composition comprising a dimesylate salt of (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.

2. The composition of claim 1 , further comprising at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar, a sugar alcohol, or a surfactant.

3. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject the composition of claim 1 .

4. The method of claim 3 , wherein the ocular disorder is glaucoma.

5. The method of claim 3 , wherein the composition is administered topically to an eye of the subject.

6. A method of reducing intraocular pressure in a subject in need thereof, comprising administering to the subject the composition of claim 1 .

7. The method of claim 6 , wherein the composition is administered topically to an eye of the subject.

8. A composition comprising a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.

9. The composition of claim 8 , further comprising at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar, a sugar alcohol, or a surfactant.

10. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject the composition of claim 8 .

11. The method of claim 10 , wherein the ocular disorder is glaucoma.

12. The method of claim 10 , wherein the composition is administered topically to an eye of the subject.

13. A method of reducing intraocular pressure in a subject in need thereof, comprising administering to the subject the composition of claim 8 .

14. The method of claim 13 , wherein the composition is administered topically to an eye of the subject.

15. A composition comprising a dimesylate salt of (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.

16. The composition of claim 15 , further comprising at least one of a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity enhancer, a sugar, a sugar alcohol, or a surfactant.

17. A method of treating an ocular disorder in a subject in need thereof, comprising administering to the subject the composition of claim 15 .

18. The method of claim 17 , wherein the ocular disorder is glaucoma.

19. The method of claim 17 , wherein the composition is administered topically to an eye of the subject.

20. A method of reducing intraocular pressure in a subject in need thereof, comprising administering to the subject the composition of claim 15 .

21. The method of claim 20 , wherein the composition is administered topically to an eye of the subject.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2024
From: AERIE PHARMACEUTICALS, INC.
To: ALCON INC.
Reel/Frame 067822/0168 →
RELEASE OF SECURITY INTEREST Recorded Sep 5, 2019
From: DEERFIELD PRIVATE DESIGN FUND III, L.P.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 050276/0807 →
RELEASE OF SECURITY INTEREST Recorded Jul 23, 2018
From: DEERFIELD PARTNERS, L.P.; DEERFIELD PRIVATE DESIGN FUND III, L.P.; DEERFIELD SPECIAL SITUATIONS FUND, L.P.; DEERFIELD MANAGEMENT COMPANY, L.P.
To: AERIE DISTRIBUTION, INC.
Reel/Frame 046431/0500 →
SECURITY INTEREST Recorded Jul 23, 2018
From: AERIE PHARMACEUTICALS, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 046432/0307 →
NUNC PRO TUNC ASSIGNMENT Recorded Jun 20, 2017
From: AERIE DISTRIBUTION, INC.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 042759/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: AERIE PHARMACEUTICALS, INC.
To: AERIE DISTRIBUTION, INC.
Reel/Frame 041754/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2016
From: KOPCZYNSKI, CASEY; LIN, CHENG-WEN; STURDIVANT, JILL MARIE; DELONG, MITCHELL A.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 039432/0096 →
Continuity (3)
Continuation 14213961 · Mar 14, 2014
Provisional Application 61787883 · Mar 15, 2013
Related Publication 20160346269A1 · Dec 1, 2016